HTPEP-001 inhalation
/ HUITAI Biomedicine
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 06, 2025
A randomized, double-blind, placebo-controlled phase I clinical study evaluating the safety, tolerability, and pharmacokinetics of HTPEP-001 inhalation in healthy subjects
(ChiCTR)
- P1 | N=34 | Completed | Sponsor: Beijing Chao-Yang Hospital, Capital Medical University; Beijing Chao-Yang Hospital, Capital Medical University
New P1 trial • Fibrosis • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases
1 to 1
Of
1
Go to page
1